Board of Directors

Ms. Burzik was appointed to the Board in June 2021. She previously served as President and Chief Executive Officer of Kinetic Concepts, Inc., a global medical device company, from 2006 until the company’s sale in 2011. Prior to this, Ms. Burzik served as President of Applied Biosystems Group and held senior executive positions at Eastman Kodak and Johnson & Johnson, including Chief Executive Officer and President of Kodak Health Imaging Systems and President of Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson company. In 2019, Ms. Burzik received the AdvaMed Lifetime Achievement Award that honors accomplishments of pioneers in the medical technology industry whose contributions have had a significant impact on patients’ lives and the industry as an essential part of America’s economy.

Currently Ms. Burzik is a member of the Board of Directors of Becton, Dickinson and Company, where she Chairs of the Quality and Regulatory Compliance Committee and serves on the Corporate Governance and Nominating Committee, and the Science, Marketing, Innovation and Technology Committees. Ms. Burzik is also a member of the Board of Directors of Haemonetics Corporation where she Chairs the Technology Committee and serves on the Audit Committee. Additionally, she serves as Executive Chairman of Gemini Bioproducts, Inc., Chairman of StemBioSys, Inc. and as Director of Xenex Disinfection Services, Inc.. Ms. Burzik previously served on the Board of Directors for the San Antonio Branch of the Dallas Federal Reserve Board, Allscripts, Inc., Bausch & Lomb, Cordis Corporation and AdvaMed.

Mr. Burris was appointed to the Orthofix Board of Directors and the Audit and Finance Committee in September 2021. In June 2022 he was appointed to the Compensation and Talent Committee. Prior to joining Orthofix, Mr. Burris served as the Senior Vice President and Chief Financial Officer (CFO) at Roche Diagnostics Corporation from 1996 through his retirement in July 2019. Mr. Burris was a member of the Global Roche Diagnostics Finance Executive Committee where he was recognized as one of their top senior leaders.

In addition to his service as Senior Vice President and CFO at Roche, Mr. Burris held various roles of increasing responsibility, including as the head of global finance for the diabetes care business where he provided financial oversight for all aspects of the business including sales and marketing, research and development, operations, regulatory and quality. In his roles, he provided strategic and business development guidance broadly across the Roche organization. Before joining Roche Diagnostics, Mr. Burris was a senior manager for Price Waterhouse LLP.

Mr. Burris is a Certified Public Accountant and has a Bachelor of Science in Accounting and Finance from Butler University. He has been instrumental in expanding and cultivating the State of Indiana Lifesciences environment while serving within numerous community organizations including being a founding board member of the Indiana Biosciences Research Institute and on the Board of Directors and Executive Committee for BioCrossroads.

Mr. Hannon joined the Orthofix Board of Directors in June 2020. A seasoned medical device executive, he currently serves as the President and Chief Executive Officer of Mainstay Medical International plc, a global company headquartered in Ireland that is focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions. Mr. Hannon has also served as President and Chief Operating Officer of NuVasive, Inc. Over the course of 12 years at NuVasive, he held various roles of increasing responsibility, including as Executive Vice President, International; and Executive Vice President, Corporate Development; and General Counsel. Mr. Hannon also serves as a director on the board of Sequana Medical NV, a publicly traded medical device company focused on the development of innovative treatment options for the management of fluid overload in liver disease, malignant ascites and heart failure. Mr. Hannon has a JD degree from Stanford University Law School and a BA degree from the University of California, Berkeley.

Mr. Hinrichs was appointed to the Board in April 2014. From 2018 to 2019, he served as Chief Financial Officer of Cibus, a privately-held agricultural biotech company. Prior to this, Mr. Hinrichs served as Executive Vice President and Chief Financial Officer of Alere Inc, a publicly traded diagnostic company, preceding its sale to Abbott Labs. From December 2010 through March 2015, he served as Chief Financial Officer of CareFusion Corporation, prior to its sale to Becton Dickinson. Mr. Hinrichs previously served as CareFusion's Senior Vice President, Global Customer Support, and as its Senior Vice President, Controller. Prior to joining CareFusion when it was spun off from Cardinal Health, Inc., he worked at Cardinal Health in various positions including Executive Vice President and Corporate Controller of Cardinal Health, and as Executive Vice President and Chief Financial Officer of its Healthcare Supply Chain Services segment. He joined Cardinal Health following more than a decade of finance and marketing roles at Merck & Co. He holds undergraduate and graduate degrees in business from Carnegie Mellon University. Mr. Hinrichs serves as a director of Integer Holdings Corporation, Acutus Medical Inc., and Outset Medical. He also serves as a director of Signifier Medical Technologies, a privately-held company.

Ms. Marks was appointed to the Board in June 2015. From 2010 to 2021, Ms. Marks served as Vice President for Health Affairs for the University of Colorado and Anschutz Medical Campus, which includes the university’s Schools of Medicine, Dental Medicine, Pharmacy, Public Health, College of Nursing and Graduate School and the University of Colorado Hospital and Children’s Hospital Colorado. Prior to her health campus leadership role, Ms. Marks spent two decades as both Senior Associate Dean for Finance and Administration at the University of Colorado’s School Of Medicine and Executive Director of University Physicians, Inc., the 501(c)(3) faculty practice plan, which offers business operations and administrative support to the University of Colorado’s School of Medicine providers. Ms. Marks has served as Chair of the Board of Directors of the University of Colorado Hospital and as a member of the board of directors of the Federal Reserve Bank of Kansas City, the Fitzsimons Redevelopment Authority, the National Institutes of Health Advisory Board on Clinical Research, the Global Down Syndrome Foundation, and the Rose Community Foundation. She also was formerly the chair of the board of the Association of American Medical Colleges (AAMC) and a member of the AAMC Advisory Panel on Research and a trustee of the University of Colorado Foundation. Ms. Marks is a graduate of the University of Colorado. In addition to these roles, Ms. Marks is also active as a national speaker on healthcare economics, healthcare system issues, and academic medicine.

Mr. Paolucci was named to the Board of Directors and appointed to the Compensation Committee in March 2016. A seasoned Human Resource (HR) executive, he has more than 20 years of global experience working directly with Boards of Directors and C-level executives to improve organizational capabilities and HR programs that result in sustained improvements in business performance. From 2015 until 2020, Mr.Paolucci served as Vice President and Chief Human Resources Officer for Halozyme Therapeutics Inc. Prior to Halozyme, Mr. Paolucci served as Executive Vice President and Chief Human Resource Officer for CareFusion. Mr. Paolucci also served as Executive Vice President of Human Resources at NuVasive, and spent five years at Life Technologies. Previously, he was head of Human Resources for the services division of Hewlett Packard and served in several leadership roles with EDS, which was acquired by Hewlett Packard. Prior to HP/EDS, Mr. Paolucci was a partner with the HR consulting firm Towers Perrin. Mr. Paolucci is a graduate of Ohio State University.

Mr. Serbousek joined Orthofix in August 2019 and became director, President and CEO in November 2019. A seasoned executive with more than 30 years’ experience in the medical device and biotech industries, Mr. Serbousek served in several leadership positions at Biomet Inc., including Worldwide President of Biomet Biologics, Worldwide Group President of Orthopedics, and President of U.S. Orthopedics. Prior to joining Biomet, he held various general management positions within Medtronic Inc., including Worldwide Division President − Spine, and Worldwide Vice President and General Manager of Biologics for their Spine and Biologics business. Additionally, Mr. Serbousek spent 13 years with DePuy Orthopedics, a Johnson & Johnson company where he served in numerous roles of increasing responsibility, including Vice President of Marketing and Product Development and Vice President of Spinal Operations. Mr. Serbousek has held numerous board positions at for profit and not-for-profit organizations. He earned his BS in Engineering from Washington State University, his MS in Bioengineering from the University of Utah, and later completed several advanced management programs including a program at the IMD International School of Management in Lausanne, Switzerland.

Mr. Sicard joined the Board in March 2018. He currently serves as the President and Chief Executive Officer, and a Board Member of Kinaxis, a global supply chain management software company that delivers cloud-based solutions to some of the world’s largest manufacturing companies, including many in the life science sector. Mr. Sicard joined Kinaxis in 1994 where he has held a number of senior management roles including Chief Product Officer, Chief Strategy Officer, Chief Operating Officer, Executive Vice President of Marketing Development and Service Operations and Vice President of Professional Services. Prior to Kinaxis, Mr. Sicard held positions at FastMAN Software Systems, and Monenco Agra. Mr. Sicard is a graduate of Concordia University, Montreal, Canada, and the Harvard Business School Advanced Management Program.

Mr. West was named to the Orthofix Board of Directors and appointed to the Compensation and Talent Development Committee in December 2021. In June 2022 he was appointed to the Audit and Finance Committee. Mr. West currently serves as the President, Chief Executive Officer and Director of Intersect ENT, Inc. (NASDAQ:XENT) a commercial stage drug-device company that pioneers local drug delivery options for ear, nose and throat surgeons. As president and CEO of Intersect ENT, he led the transformation of the business from a single technology player to a more comprehensive ENT company, resulting in a definitive agreement to be acquired by Medtronic for $1.1B.

Prior to Intersect ENT, Mr. West served as Division President, Diagnostic Solutions at Hologic, Inc. Additionally, he had a 23-year career at Johnson & Johnson in various domestic and international roles of increasing responsibility across devices, pharmaceuticals and consumer products. Most recently he served as Worldwide Vice President, Strategy and Business Development, Diabetes Solutions Companies. He also served as Division President for J&J’s LifeScan diabetes company in both North America and in Europe, Middle East and Africa.

Mr. West has an A.B. in Politics and Economics from Princeton University and a M.B.A. from the Wharton School of the University of Pennsylvania in Marketing and Strategic Management. He is a member of the Board of Directors of the Advanced Medical Technology Association (AdvaMed).